Cumberland Pharmaceuticals' Caldolor Approved for Expanded Use in Postoperative Pain Management
- Cumberland Pharmaceuticals' Caldolor® now has FDA approval for postoperative pain management in patients aged 3 months and older.
- The expanded indication allows Caldolor to manage mild to moderate pain and support opioid analgesics for severe pain.
- Cumberland launched a new website providing resources for healthcare professionals about Caldolor's role in non-opioid pain management.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has received FDA approval for an expanded indication for its flagship ibuprofen product, Caldolor®. This approval allows Caldolor to be utilized for managing postoperative pain in both adult and pediatric patients aged 3 months and older, representing a significant advancement in non-opioid analgesic treatment options. Furthermore, the product can now be employed for mild to moderate pain management and as an adjunct to opioid analgesics for moderate to severe pain, enhancing its current application for fever reduction.
Highlighting Non-Opioid Pain Management
This expanded indication comes at a crucial time as the healthcare community actively seeks ways to reduce reliance on opioids amid the ongoing opioid crisis. Postoperative pain management remains a vital area of focus, bridging the gap between effective care and the imperative to mitigate opioid-related risks. Cumberland's strategic move reflects a commitment to innovation in pain relief, catering to a pressing public health concern while ensuring patient safety.
Introducing the Caldolor Healthcare Portal
In addition to the product announcement, Cumberland has launched a new dedicated website designed for healthcare professionals. This resource focuses on multimodal, opioid-sparing strategies, providing critical information about Caldolor's role in perioperative care. The site comprises essential safety data, dosing guidelines, and reimbursement support, fostering an environment for healthcare providers to further educate themselves on integrating non-opioid therapies in clinical practice.
A Robust Alternative
Caldolor stands out as the first FDA-approved intravenous therapy for fever, showcasing its versatility in managing patient care in surgical environments. However, it is important to note that the product is contraindicated for individuals with known hypersensitivity to ibuprofen or NSAIDs, along with those who have a history of allergic reactions to aspirin. For more resources and information, healthcare professionals are invited to visit www.caldolor.com.